BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

844 related articles for article (PubMed ID: 26470624)

  • 1. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
    Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
    J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
    Holcomb ZE; Porter ML; Kimball AB
    Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
    Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
    JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics for hidradenitis suppurativa: an update.
    Włodarek K; Ponikowska M; Matusiak Ł; Szepietowski JC
    Immunotherapy; 2019 Jan; 11(1):45-59. PubMed ID: 30702012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
    Maarouf M; Clark AK; Lee DE; Shi VY
    J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of biological treatments in patients with hidradenitis suppurativa.
    Martin-Ezquerra G; Masferrer E; Masferrer-Niubò M; Ferran M; Sánchez-Regaña M; Collgros H; Bordas X; Notario J; Alsina M; Gil I; Izquierdo N; Aparicio G; Mollet J; Garcia-Patos V; Pujol RM
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):56-60. PubMed ID: 24629001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
    Shanmugam VK; Mulani S; McNish S; Harris S; Buescher T; Amdur R
    Int J Dermatol; 2018 Jan; 57(1):62-69. PubMed ID: 29130482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
    Porter ML; Golbari NM; Lockwood SJ; Kimball AB
    Semin Cutan Med Surg; 2018 Sep; 37(3):182-189. PubMed ID: 30215636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy.
    Samycia M; Brassard A
    J Cutan Med Surg; 2013 Oct; 17 Suppl 1():S23-32. PubMed ID: 24144253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
    van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
    J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Hidradenitis Suppurative (Part II): Treatment.
    Martorell A; García FJ; Jiménez-Gallo D; Pascual JC; Pereyra-Rodríguez J; Salgado L; Villarrasa E
    Actas Dermosifiliogr; 2015 Nov; 106(9):716-24. PubMed ID: 26277040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
    Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
    Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
    J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013.
    Sbidian E; Hotz C; Seneschal J; Maruani A; Amelot F; Aubin F; Paul C; Beylot Barry M; Humbert P; Dupuy A; Caux F; Dupin N; Modiano P; Lepesant P; Ingen-Housz-Oro S; Mahé E; Bachelez H; Chosidow O; Wolkenstein P
    Br J Dermatol; 2016 Mar; 174(3):667-70. PubMed ID: 26406350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 43.